| Assay ID | Title | Year | Journal | Article |
|---|
| AID219907 | Inhibition of currents generated by 50 uM kainate in Xenopus oocytes injected with rat brain mRNA | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID145121 | Binding affinity of compound against strychnine-insensitive glycine site on NMDA receptor in rat brain membrane using [3H]glycine as radioligand | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
| 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID143620 | In vitro inhibition of the specific binding of [3H]Gly to N-methyl-D-aspartate glutamate receptor 1 in rat whole brain membranes except cerebellum | 1996 | Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
| Novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-pyrido[2,3-b]pyrazinedione and related compounds. |
| AID92352 | Binding affinity was determined against ionotropic glutamate receptor AMPA in rat brain synaptic membranes using [3H]AMPA as radioligand | 1995 | Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
| Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act |
| AID1859124 | Displacement of [3H]glycine from AMPA receptor (unknown origin) | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. |
| AID132055 | Effective dose of the intraperitoneally administered compound required to protect 50% of DBA/2 mice from tonico-clonic convulsion | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. |
| AID143617 | In vitro affinity for N-methyl-D-aspartate glutamate receptor 1 using [3H]5,7-dichlorokynurenate([3H]-DCKA) as ligand | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
| 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. |
| AID143295 | Displacement of [3H]DCKA from N-methyl-D-aspartate glutamate receptor of rat cortical membrane | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. |
| AID132103 | Tested in vivo as the dose which protected 50% of the animals from a tonic convulsion (six male CDI mice/dose of compound) after intraperitoneal administration in DBA test | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
| 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. |
| AID92508 | The compound was tested for its affinity for Ionotropic glutamate receptor AMPA in in vitro binding assay on rat cortical membrane preparations using [3H]AMPA as ligand | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
| 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. |
| AID244246 | Selectivity as ratio of Ki for N-methyl-D-aspartate glutamate receptor and ionotropic glutamate receptor AMPA | 2004 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group. |
| AID92783 | Inhibition of [3H]AMPA binding to Ionotropic glutamate receptor from rat whole brain. | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
| 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID92776 | In vitro inhibition of the specific binding of [3H]AMPA to Ionotropic glutamate receptor AMPA in rat whole brain membranes in the presence of 100 uM KSCN | 1996 | Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
| Novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-pyrido[2,3-b]pyrazinedione and related compounds. |
| AID143306 | Binding affinity for N-methyl-D-aspartate glutamate receptor | 2000 | Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
| Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden. |
| AID196109 | The compound was tested for anti-KA-Induced Neurotoxicity in rat primary hippocampal cultures. | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
| 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID237720 | Solubility at pH 7.4 | 2004 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group. |
| AID112514 | In vivo activity determined by Maximum electroshock induced seizures (MES) assay in mice after ip administration | 1999 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
| Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo. |
| AID496834 | Displacement of [3H]AMPA from AMPA receptor in rat cortical membrane | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| AID1859123 | Displacement of [3H]kainate from AMPA receptor (unknown origin) | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. |
| AID92370 | Displacement of [3H]AMPA from Ionotropic glutamate receptor AMPA of rat cortical membranes | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID142994 | The compound was tested for its ability to inhibit [3H]Gly binding to N-methyl-D-aspartate glutamate receptor from rat whole brain. | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
| 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID184019 | In vitro inhibitory effect on AMPA-induced DC potential in rat cortical slices; active | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. |
| AID144764 | In vitro binding affinity towards NMDA glutamate receptor using [3H]5,7-dichlorokynurenate as ligand on rat cortical membrane preparations | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
| Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. |
| AID92371 | In vitro binding affinity towards ionotropic glutamate receptor AMPA using [3H]AMPA as radioligand in rat cortical membrane preparations | 1999 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
| Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo. |
| AID113370 | In vivo effective dose required to protect 6 male CD1 mice against tonic convulsions following iv administration for a pretreatment time of 5 min | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID223296 | Dose which protected 50 % of the mice from a tonic convulsion. | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
| Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. |
| AID234757 | Selectivity between AMPA/kainate receptor and NMDA/glycine receptor | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
| Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. |
| AID143457 | Ratio of binding affinity towards N-methyl-D-aspartate glutamate receptor (NMDA-R) to that of AMPA-R | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. |
| AID145322 | Binding affinity towards NMDA receptor was determined in rat whole brain membrane using NMDA-sensitive [3H]Glu as radioligand | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
| Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds. |
| AID113366 | In vivo effective dose required to protect 6 male CD1 mice against tonic convulsions following ip administration for a pretreatment time of 30 min | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID113373 | In vivo effective dose required to protect 6 male CD1 mice against tonic convulsions following iv administration for a pretreatment time of 60 min | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID143302 | Binding affinity towards glycine binding site on NMDA receptor was determined in rat whole brain membrane using strychnine-insensitive [3H]Gly as radioligand | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
| Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds. |
| AID93118 | Antagonistic activity against rat ionotropic glutamate receptor ionotropic kainate in xenopus oocytes | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
| Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. |
| AID132057 | Effective dose of the intraperitoneally administered compound required to protect 50% of mice from tonic convulsion caused by maximal electric shock (MES) | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. |
| AID73794 | Displacement of [3H]DCKA from glycine NMDA receptor of rat cortical membranes | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID113961 | Anticonvulsant activity in male CD1 mice | 2000 | Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
| Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden. |
| AID92644 | Binding affinity towards Ionotropic glutamate receptor AMPA was determined in rat whole brain membrane using [3H]AMPA as radioligand | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
| Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds. |
| AID496835 | Displacement of [3H]kainate from kainate receptor in rat cortical membrane | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| AID1859112 | Displacement of [3H]AMPA from AMPA receptor (unknown origin) | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. |
| AID31451 | Tested for in vitro binding affinity against AMPA receptor using [3H]AMPA binding assay | 1998 | Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
| 5-Aminomethylquinoxaline-2,3-diones. Part I: A novel class of AMPA receptor antagonists. |
| AID145120 | Binding affinity of compound against NMDA receptor binding site in rat brain membrane using [3H]glutamate as radioligand | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
| 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID496837 | Inhibition of NMDA receptor glycine site from rat cortical membrane | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| AID223293 | Dose which protected 50 % of the mice from a tonic convulsion. | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
| Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. |
| AID223295 | Dose which protected 50 % of the mice from a tonic convulsion, pretreatment was before 3 hr by i.v. administration in MES test. | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
| Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. |
| AID496836 | Inhibition of NMDA receptor glutamate site from rat cortical membrane | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. |
| AID239653 | Displacement of [3H]AMPA (5 nM) from ionotropic glutamate receptor AMPA of rat cerebral cortex synaptic membrane preparation | 2004 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group. |
| AID93736 | Binding affinity against kainate receptor in rat brain membrane using [3H]kainate as radioligand | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
| 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID132105 | Tested in vivo as the dose which protected 50% of the animals from a tonic convulsion (six male CDI mice/dose of compound) after intraperitoneal administration in MES test | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
| 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. |
| AID92210 | Antagonistic activity against Ionotropic glutamate receptor AMPA using kainate-evoked current in Xenopus oocytes injected with rat brain mRNA | 2000 | Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
| Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden. |
| AID93738 | Binding affinity towards Ionotropic glutamate receptor kainate was determined in rat cortical membrane using [3H]KA as radioligand | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
| Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds. |
| AID92372 | Affinity towards Ionotropic glutamate receptor AMPA using [3H]AMPA as ligand on rat cortical membrane preparations | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
| Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. |
| AID95026 | Inhibitory activity against generation of currents by 50 uM kainate in Xenopus oocytes injected with rat brain mRNA | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. |
| AID252187 | In vivo protective effect in focal ischemia rat model was determined after intravenous dosage at 15 mg/kg/h for 4 hr | 2004 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group. |
| AID31606 | Binding affinity against AMPA receptor in rat brain membrane using [3H]-AMPA as radioligand | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
| 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID145268 | In vitro binding affinity towards glycine modulatory site on the NMDA receptors using [3H]DCKA as radioligand in rat cortical membrane preparations | 1999 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
| Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo. |
| AID92643 | Binding affinity for ionotropic glutamate receptor AMPA using [3H]AMPA as radioligand, bound to synaptic membranes prepared from rat cerebral cortex | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. |
| AID169552 | Neuroprotective effect in rat after iv administration at a dose of 15 mg/kg/h for 4 h | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. |
| AID113368 | In vivo effective dose required to protect 6 male CD1 mice against tonic convulsions following iv administration for a pretreatment time of 30 min | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
| Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. |
| AID92509 | Displacement of [3H]AMPA from Ionotropic glutamate receptor AMPA of rat cortical membranes | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. |
| AID132106 | Tested in vivo as the dose which protected 50% of the animals from a tonic convulsion (six male CDI mice/dose of compound) after intravenous administration in MES test | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
| 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. |
| AID180660 | The compound was tested for its inhibition of currents generated by 50 uM Kainate in Xenopus oocytes injected with rat brain mRNA | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
| 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. |
| AID142991 | The compound was tested for its ability to inhibit [3H]Glu binding to N-methyl-D-aspartate glutamate receptor from rat whole brain. | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
| 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. |
| AID143474 | Antagonistic activity against N-methyl-D-aspartate glutamate receptor 1 in Xenopus oocytes | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
| Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. |
| AID92348 | Binding affinity for Ionotropic glutamate receptor AMPA | 2000 | Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
| Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508628 | Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1508629 | Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1508627 | Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |